Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company advancing novel therapies that modulate regulatory T cells (Tregs) to treat neurodegenerative, autoimmune, and metabolic disorders. This page serves as the definitive source for official updates and analysis on COYA's progress in developing innovative immunology solutions.
Investors and researchers will find timely updates on clinical trial milestones, regulatory developments, and strategic collaborations. Our curated news collection includes verified information on therapy pipeline advancements, intellectual property updates, and financial disclosures essential for evaluating this innovative biotech company.
Key content focuses on COYA's multi-modality Treg platform developments, partnership announcements with research institutions, and progress toward addressing high-need conditions like ALS and Alzheimer's disease. All materials maintain journalistic rigor while avoiding speculative commentary.
Bookmark this page for structured access to COYA's latest scientific advancements and corporate developments. Check regularly for updates on this pioneering company's efforts to translate Treg research into transformative therapies.
Rhea-AI Summary
Coya Therapeutics presents data demonstrating compromised Treg function and increased inflammatory markers in FTD patients. COYA 302 aims to restore Treg function and target inflammation in neurodegenerative diseases like FTD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
-
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces the presentation of data on chronic systemic inflammation and dysfunctional Tregs in Frontotemporal Dementia patients at the AD/PD 2024 Conference. Dr. Alireza Faridar will showcase the role of the immune system in FTD pathology, funded by a grant from Houston Methodist. Coya plans to file an IND for COYA 302, a therapeutic candidate, in 4Q24.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.86%
Tags
-
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) presents novel biomarker data in ALS patients correlating to disease progression and survival. Dr. Stanley Appel to present at the Society of Neuroimmune Pharmacology Conference on March 12th, 2024, highlighting the potential of the oxidative stress biomarker candidate. The company aims to enhance Treg function with biologics, offering new insights for patient monitoring and therapy efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
Rhea-AI Summary
Coya Therapeutics, Inc. (NASDAQ: COYA) expands COYA 302 pipeline into Alzheimer's Disease, leveraging synergistic mode of action with LD IL-2 and CTLA4-Ig. The partnership with Dr. Reddy's Laboratories in ALS is valued at up to $733 million. Ongoing double-blind trial for LD IL-2 in AD aims to support COYA 302 development. The company plans to file INDs for ALS and FTD in 2024, with additional clinical updates and expansion of combination therapies beyond COYA 302.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
-
Rhea-AI Summary
Coya Therapeutics, Inc. (NASDAQ: COYA) expands patent estate with a license from University of Nebraska Medical Center for multiple low dose interleukin-2 (ld IL-2) combinations, including ld IL-2 + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). The combination results in a 4-6 fold synergistic increase in Tregs, enhancing Treg function and lowering inflammation. UNeMed will receive payments and royalties. The license strengthens Coya's multi-pathway approach in developing immunomodulatory drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
-
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces that Dr. Stanley Appel will present at the Society of Neuroimmune Pharmacology Conference on March 11, 2024. The presentation will discuss the potential of combination immunotherapy in treating neuroinflammatory conditions like ALS, FTD, and PD. Dr. Appel will highlight the prevalence of systemic immune and inflammatory factors in ALS and the potential of COYA 302 therapy. The presentation aims to share findings on targeting multiple immunomodulatory pathways to overcome the redundancy of the immune system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces participation in Chardan Capital Market’s biotechnology Leadership Call Series. The company's CEO, CBO, and CMO will discuss their pioneering drug development efforts in Treg-enhancing therapies for neurodegenerative diseases, specifically COYA 302. Interested investors can request attendance to the live virtual event by emailing Chardan. A replay of the session will be available on Coya’s website following the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
-
Rhea-AI Summary
Coya Therapeutics, Inc. announces the expansion of its pipeline to include frontotemporal dementia and Parkinson's disease in addition to ALS. The company has developed COYA 302, a proprietary biologic combination immunotherapy targeting multiple pathways to address the proinflammatory environment underlying these diseases. The company has also provided strong and productive milestone and catalyst updates for 2024, with cash runway guidance extending into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
-
Rhea-AI Summary
DISCO Pharmaceuticals, a specialist biotech company, has emerged from stealth with a transformative surfaceome discovery technology to identify new targets and develop first-in-class drugs for cancer treatment. The company has successfully raised seed financing of EUR 20 million and is backed by a world-leading investor syndicate. DISCO has completed the first-ever map of the surfaceome of Small Cell Lung Cancer and is developing proprietary antibody-based treatments for it. The company is also working on Microsatellite-Stable Colorectal Cancer and has a pipeline of further undisclosed programs. The experienced team, led by CEO Roman Thomas, includes leading biopharma executives Dieter Weinand and Carsten Reinhardt. The company's surfaceome mapping platform has the potential to transform oncology treatment options and improve outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
Rhea-AI Summary
Coya Therapeutics, Inc. (COYA) has successfully obtained constructive feedback and reached alignment with the FDA on key areas involved in the development of COYA 302, a dual-mechanism investigational biologic combination therapy for the treatment of ALS. This significant step paves the way for the submission of the IND application to the FDA in the second quarter of 2024 and the initiation of a well-controlled, double-blind clinical trial of COYA 302 in ALS patients. The company has secured a cash runway into 2026 through recent out-licensing and private placement transactions, positioning it to deliver value to patients and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
Coya Therapeutics, Inc.
Nasdaq:COYA
COYA Rankings
COYA Stock Data
87.97M
14.66M
7.03%
26.72%
1.63%
Biotechnology
Pharmaceutical Preparations
United States
HOUSTON